CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 15 No. 8
Washinton Insight 

EPA's Dioxin Assessment May Overstate Risk of Cancer

August 1, 2006

WASHINGTON—An evaluation of the US Environmental Protection Agency's most recent assessment of dioxin has concluded that EPA understated the uncertainly about the chemical's health risks and may have overstated the risk of human cancer. The report by the National Research Council (NRC) found that EPA provided a comprehensive review of the scientific data but failed to sufficiently quantify the risks or adequately justify the assumptions used to support them. The NRC is the research arm of the National Academy of Sciences and National Academy of Engineering.

Dioxin—its most toxic form is TCDD, found in the herbicide Agent Orange—and dioxin-like compounds enter the environment from several sources, which include combustion, metal processing, and chemical manufacturing and processing. Human exposure to the chemicals occurs most often through the consumption of beef, pork, fish, and dairy products. Occupational or accidental exposure can cause far higher exposure levels than occur through the food chain. However, evidence suggests that human exposure to dioxin and dioxin-like chemicals has declined in recent years.

In 1985, EPA classified dioxin as a "probable human carcinogen," and in 1997, the WHO's International Agency for Research on Cancer designated dioxin as "carcinogenic to humans." Five years ago, the National Toxicology Program upgraded its classification of dioxin to "carcinogenic in humans," and the EPA in its 2003 draft reassessment raised the classification of TCDD to "known to cause human cancer."

EPA had used a "linear" model to determine risk based on higher-dose exposure data from exposed workers, an approach that usually results in higher risk estimates than those using nonlinear models where biologic responses do not vary proportionally with dose. The report recommended that EPA use both nonlinear and linear methods to assess risk, including compelling new animal data released after the EPA completed its 2003 reassessment. The new data, combined with substantial evidence that dioxin does not directly damage DNA, provides an adequate justification for using nonlinear methods to estimate human cancer risks of dioxin at relatively low levels of exposure, the report stated. The panel did agree unanimously that TCDD fits the definition for likely to be carcinogenic to humans, and it added that the public health implications of the two terms appear identical. Nonetheless, members urged EPA to reconsider whether its 2003 classification of TCDD as carcinogenic to humans met its 2005 cancer guidelines.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy